A Phase Ib Clinical Study With Extension Phase to Evaluate Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC Patients
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Fruquintinib (Primary) ; Genolimzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genor Biopharma
- 25 Nov 2019 Status changed from not yet recruiting to recruiting.
- 03 Dec 2018 New trial record
- 29 Oct 2018 According to a Genor Biopharma media release, the study is expected to begin enrolling patients in China in late 2018. Data from this study may lead to subsequent Phase III registration studies to establish the safety and efficacy of the combination in China.